PHI and Boston Children’s Hospital – a Harvard Medical School teaching hospital – have signed an agreement to evaluate PHI’s HoloMonitor®technology for applications in cell-based cancer research. During the evaluation period, PHI will provide Boston Children’s Hospital with HoloMonitor M4.5 instrumentation and technical support.
“The agreement with Boston Children’s Hospital and other opinion leading research institutions is a key component of our strategic marketing to establish HoloMonitor technology within preclinical research. We look forward to the results of the evaluation and to work with world class cancer researchers at the hospital,” said CEO Peter Egelberg.
ABOUT BOSTON CHILDREN’S HOSPITAL